- Home
- ZYME vs BV Comparison
ZYME vs BV Comparison
Compare ZYME & BV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- BV
- Stock Information
- Founded
- ZYME 2003
- BV 1939
- Country
- ZYME United States
- BV United States
- Employees
- ZYME N/A
- BV N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- BV Business Services
- Sector
- ZYME Health Care
- BV Consumer Discretionary
- Exchange
- ZYME Nasdaq
- BV Nasdaq
- Market Cap
- ZYME 1.2B
- BV 1.4B
- IPO Year
- ZYME 2017
- BV 2018
- Fundamental
- Price
- ZYME $16.46
- BV $11.83
- Analyst Decision
- ZYME Strong Buy
- BV Buy
- Analyst Count
- ZYME 7
- BV 6
- Target Price
- ZYME $22.00
- BV $17.98
- AVG Volume (30 Days)
- ZYME 889.7K
- BV 704.5K
- Earning Date
- ZYME 11-06-2025
- BV 11-19-2025
- Dividend Yield
- ZYME N/A
- BV N/A
- EPS Growth
- ZYME N/A
- BV N/A
- EPS
- ZYME N/A
- BV 0.12
- Revenue
- ZYME $134,481,000.00
- BV $2,698,700,000.00
- Revenue This Year
- ZYME $99.52
- BV $0.10
- Revenue Next Year
- ZYME N/A
- BV $2.09
- P/E Ratio
- ZYME N/A
- BV $98.71
- Revenue Growth
- ZYME 116.21
- BV N/A
- 52 Week Low
- ZYME $9.03
- BV $11.71
- 52 Week High
- ZYME $19.98
- BV $18.89
- Technical
- Relative Strength Index (RSI)
- ZYME 36.30
- BV 28.68
- Support Level
- ZYME $17.27
- BV $12.10
- Resistance Level
- ZYME $19.98
- BV $12.27
- Average True Range (ATR)
- ZYME 0.76
- BV 0.29
- MACD
- ZYME -0.27
- BV -0.07
- Stochastic Oscillator
- ZYME 11.48
- BV 7.83
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About BV BrightView Holdings Inc.
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.